Zobrazeno 1 - 10
of 83
pro vyhledávání: '"NORIYUKI EBI"'
Autor:
Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100655- (2024)
Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who
Externí odkaz:
https://doaj.org/article/266c2a21ca60472ab272511e35e74652
Autor:
Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100514- (2023)
Introduction: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for
Externí odkaz:
https://doaj.org/article/4876c2feeaf34060b78e84539b872f0e
Autor:
Naoko Sueoka‐Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Abstract Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or pr
Externí odkaz:
https://doaj.org/article/9fdb0934bf3d40bbb7a19d2b98a77955
Autor:
Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15–30% of patients treated with EGFR-TK
Externí odkaz:
https://doaj.org/article/c4884704459847fb8984edec803f99a8
Autor:
Kiichiro Ninomiya, MD, PhD, Shunsuke Teraoka, MD, Yoshitaka Zenke, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Yukiko Nakamura, MD, Yusuke Okuma, MD, PhD, Akihiro Tamiya, MD, Kaname Nosaki, MD, Masahiro Morise, MD, PhD, Keiju Aokage, MD, Yuko Oya, MD, Toshiyuki Kozuki, MD, PhD, Tomohiro Sakamoto, MD, PhD, Kentaro Tanaka, MD, PhD, Hisashi Tanaka, MD, PhD, Junko Tanizaki, MD, PhD, Satoru Miura, MD, PhD, Hideaki Mizutani, MD, Eisaku Miyauchi, MD, PhD, Ou Yamaguchi, MD, PhD, Noriyuki Ebi, MD, Yasushi Goto, MD, PhD, Takaaki Sasaki, MD, PhD, Haruko Daga, MD, PhD, Satoshi Morita, PhD, Takeharu Yamanaka, PhD, Shinsuke Amano, BCom, Kazuo Hasegawa, BFA, Chiyo K. Imamura, PhD, Kenichi Suzuki, PhD, Kazuko Nakajima, PhD, Hitomi Nishimoto, MN, Satoshi Oizumi, MD, PhD, Toyoaki Hida, MD, PhD, Katsuyuki Hotta, MD, PHD, MPH, Yuichi Takiguchi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100107- (2021)
Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee. The purp
Externí odkaz:
https://doaj.org/article/5ceda8a606294ebc9bef7784fdc89eeb
Autor:
Nobuyuki Yamamoto, Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, Eriko Miyawaki, Junichi Shimizu, Tomohiro Ozaki, Daichi Fujimoto, Ryo Toyozawa, Atsushi Nakamura, Toshiyuki Kozuki, Kentaro Tanaka, Shunsuke Teraoka, Kazuhiro Usui, Kazumi Nishino, Osamu Hataji, Keiichi Ota, Noriyuki Ebi, Sho Saeki, Yuki Akazawa, Motoyasu Okuno, Kazuhiko Nakagawa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Studies have suggested that chemotherapy after immune checkpoint inhibitors may confer an improved response for non–small cell lung cancer (NSCLC). However, potential selection bias in such studies has not been addressed. We therefore ap
Externí odkaz:
https://doaj.org/article/a1e05f97528e462ca8d6640b3c0bea4b
Autor:
NOBUMITSU IKEUCHI, FUMIYASU IGATA, ERIKO KINOSHITA, TOSHIAKI KAWABATA, IBUN TAN, YUSUKE OSAKI, RIKAKO OTSUKA, RINTARO ON, TAKATO IKEDA, AKIRA NAKAO, TOMOYA SASAKI, TAKASHI AOYAMA, RYOSUKE HIRANO, TAISHI HARADA, NORIYUKI EBI, MASAKI FUJITA, HIROYUKI INOUE
Publikováno v:
Anticancer Research. 43:713-724
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aedb28b145f9c8c6e025dab8907dff80
https://doi.org/10.21873/anticanres.16210
https://doi.org/10.21873/anticanres.16210
Autor:
Kaname Nosaki, Jun Sakakibara-Konishi, Ichiro Nakachi, Yoshitaka Zenke, Kageaki Taima, Keisuke Kirita, Kiyotaka Yoh, Shunta Mori, Genichiro Ishii, Shoichi Kuyama, Tatsuro Fukuhara, Shingo Matsumoto, Shogo Kumagai, Hiroki Izumi, Yuji Shibata, Seiji Niho, Noriyuki Ebi, Takaya Ikeda, Jie Liu, Tokiko Nakai, Masahiro Kodani, Haruko Daga, Terufumi Kato, Tetsuya Sakai, Koichi Goto, Atsushi Ohtsu, Kosuke Tanaka, Eri Sugiyama, Atsushi Nakamura, Kana Watanabe, Takuma Hayashida, Isamu Okamoto, Susumu Kobayashi, Kazumi Nishino, Kumiko Hayashi, Naoki Furuya, Hibiki Udagawa, Akira Yamasaki
Publikováno v:
Nature. 600:319-323
Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-cell lung cancer (NSCLC)1. However, such oncogenic drivers are not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91a19f21c49272718231894afcff24f4
https://doi.org/10.1038/s41586-021-04135-5
https://doi.org/10.1038/s41586-021-04135-5
Autor:
Keisuke Aoe, Shoichi Kuyama, Koji Inoue, Kazuhiro Yatera, Takayuki Suetsugu, Minoru Fukuda, Nobukazu Fujimoto, Kosuke Kashiwabara, Noriyuki Ebi, Fumihiro Tanaka, Daijiro Harada, Akihiro Nishiyama, Chiharu Yoshii, Hitomi Umeguchi, Hironori Yoshida, Atsushi Kawaguchi, Chiho Nakashima, Katsumi Nakatomi, Kentaro Iwanaga, Ayako Takamori, Genju Koh, Naoko Sueoka-Aragane, Nobuhiko Seki, Hidetaka Uramoto, Naohisa Matsumoto, Sunao Ushijima, Kaname Nosaki
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Cancer Medicine
Cancer Medicine
Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a231f467d3229c38e0783da336fd1667
https://doi.org/10.1002/cam4.3929
https://doi.org/10.1002/cam4.3929
Autor:
Yuko Oya, Miyako Satouchi, Keiju Aokage, Noriyuki Ebi, Katsuyuki Hotta, Yuichi Takiguchi, Katsuyuki Shirai, Yusuke Okuma, Kaname Nosaki, Tomohiro Sakamoto, Tetsuo Nonaka, Kiichiro Ninomiya, Toshiyuki Kozuki, Hitoshi Ishikawa
Publikováno v:
Haigan. 61:95-99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a12dafcd69afa5d07f8f0324f2ca8c6
https://doi.org/10.2482/haigan.61.95
https://doi.org/10.2482/haigan.61.95